Study: NCT05113004

Intervention type: DRUG
Group type: OTHER
Intervention: Hydroxychloroquine 400mg/d
Description: Hydroxychloroquine (HCQ) is a 4-aminoquinoline belonging to the group of antimalarial agents. Its immunomodulatory activity on B-cells has mainly been attributed to its inhibition of antigen presentation, cytokine production, and recently on Toll-like receptor signaling and IFN secretion that drives B cell activation.

Intervention type: DRUG
Group type: OTHER
Intervention: Hydroxychloroquine 400mg/d
Description: Hydroxychloroquine (HCQ) is a 4-aminoquinoline belonging to the group of antimalarial agents. Its immunomodulatory activity on B-cells has mainly been attributed to its inhibition of antigen presentation, cytokine production, and recently on Toll-like receptor signaling and IFN secretion that drives B cell activation.

Intervention type: DRUG
Group type: OTHER
Intervention: Hydroxychloroquine 400mg/d
Description: Hydroxychloroquine (HCQ) is a 4-aminoquinoline belonging to the group of antimalarial agents. Its immunomodulatory activity on B-cells has mainly been attributed to its inhibition of antigen presentation, cytokine production, and recently on Toll-like receptor signaling and IFN secretion that drives B cell activation.

Intervention type: DRUG
Group type: OTHER
Intervention: Hydroxychloroquine 400mg/d
Description: Hydroxychloroquine (HCQ) is a 4-aminoquinoline belonging to the group of antimalarial agents. Its immunomodulatory activity on B-cells has mainly been attributed to its inhibition of antigen presentation, cytokine production, and recently on Toll-like receptor signaling and IFN secretion that drives B cell activation.

Intervention type: DRUG
Group type: OTHER
Intervention: Leflunomide 20mg/d
Description: Leflunomide (LEF) is a derivative of isoxazole and is converted into an active metabolite which blocks de novo synthesis of pyrimidines in activated T lymphocytes, thereby inhibiting T cell proliferation and consequently T cell-dependent B cell formation of autoantibodies.

Intervention type: DRUG
Group type: OTHER
Intervention: Leflunomide 20mg/d
Description: Leflunomide (LEF) is a derivative of isoxazole and is converted into an active metabolite which blocks de novo synthesis of pyrimidines in activated T lymphocytes, thereby inhibiting T cell proliferation and consequently T cell-dependent B cell formation of autoantibodies.

Intervention type: DRUG
Group type: OTHER
Intervention: Leflunomide 20mg/d
Description: Leflunomide (LEF) is a derivative of isoxazole and is converted into an active metabolite which blocks de novo synthesis of pyrimidines in activated T lymphocytes, thereby inhibiting T cell proliferation and consequently T cell-dependent B cell formation of autoantibodies.

Intervention type: DRUG
Group type: OTHER
Intervention: Mycophenolate mofetil 2000mg/d
Description: Mycophenolate mofetil (MMF) is a morpholinoethyl ester of mycophenolic acid which blocks proliferation of lymphocytes by inhibiting the de novo pathway of purine biosynthesis (Allison, 2000).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of Hydroxychloroquine 400mg/d
Description: Placebo of Hydroxychloroquine (HCQ) is a 4-aminoquinoline belonging to the group of antimalarial agents. Its immunomodulatory activity on B-cells has mainly been attributed to its inhibition of antigen presentation, cytokine production, and recently on Toll-like receptor signaling and IFN secretion that drives B cell activation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of Hydroxychloroquine 400mg/d
Description: Placebo of Hydroxychloroquine (HCQ) is a 4-aminoquinoline belonging to the group of antimalarial agents. Its immunomodulatory activity on B-cells has mainly been attributed to its inhibition of antigen presentation, cytokine production, and recently on Toll-like receptor signaling and IFN secretion that drives B cell activation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of Leflunomide 20mg/d
Description: Placebo of Leflunomide (LEF) is a derivative of isoxazole and is converted into an active metabolite which blocks de novo synthesis of pyrimidines in activated T lymphocytes, thereby inhibiting T cell proliferation

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo of Leflunomide 20mg/d
Description: Placebo of Leflunomide (LEF) is a derivative of isoxazole and is converted into an active metabolite which blocks de novo synthesis of pyrimidines in activated T lymphocytes, thereby inhibiting T cell proliferation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of Leflunomide 20mg/d
Description: Placebo of Leflunomide (LEF) is a derivative of isoxazole and is converted into an active metabolite which blocks de novo synthesis of pyrimidines in activated T lymphocytes, thereby inhibiting T cell proliferation

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo of Leflunomide 20mg/d
Description: Placebo of Leflunomide (LEF) is a derivative of isoxazole and is converted into an active metabolite which blocks de novo synthesis of pyrimidines in activated T lymphocytes, thereby inhibiting T cell proliferation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of Mycophenolate mofetil 2000mg/d
Description: Placebo of Mycophenolate mofetil (MMF) is a morpholinoethyl ester of mycophenolic acid which blocks proliferation of lymphocytes by inhibiting the de novo pathway of purine biosynthesis (Allison, 2000).

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo of Mycophenolate mofetil 2000mg/d
Description: Placebo of Mycophenolate mofetil (MMF) is a morpholinoethyl ester of mycophenolic acid which blocks proliferation of lymphocytes by inhibiting the de novo pathway of purine biosynthesis (Allison, 2000).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of Mycophenolate mofetil 2000mg/d
Description: Placebo of Mycophenolate mofetil (MMF) is a morpholinoethyl ester of mycophenolic acid which blocks proliferation of lymphocytes by inhibiting the de novo pathway of purine biosynthesis (Allison, 2000).

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo of Mycophenolate mofetil 2000mg/d
Description: Placebo of Mycophenolate mofetil (MMF) is a morpholinoethyl ester of mycophenolic acid which blocks proliferation of lymphocytes by inhibiting the de novo pathway of purine biosynthesis (Allison, 2000).